ATTENUATION OF DERMAL TOXICITY OF DOXORUBICIN BY LIPOSOME ENCAPSULATION
- 1 January 1983
- journal article
- research article
- Vol. 67 (5) , 481-484
Abstract
The severe tissue damage which occurs when doxorubicin (Dxn) is extravasated during infusion has been attenuated by encapsulating the drug in anionic liposomes. Mice were injected intradermally with either 0.05 or 0.10 mg of Dxn in the free or liposome-entrapped form. At both dose levels, the animals receiving free drug developed dermal lesions at a higher frequency and of a greater severity than did those animals receiving Dxn-liposomes. Determination of tissue-associated fluorescence indicated that free Dxn was removed from the area of the dermal injection more rapidly than was the liposome-entrapped drug. The data suggest that the dermal toxicity of Dxn may be determined more by its mode of disposition than by the absolute amount of drug in tissue. [Dxn is an anticancer agent.].This publication has 4 references indexed in Scilit:
- PHARMACOLOGIC ANTIDOTES TO EXPERIMENTAL DOXORUBICIN SKIN TOXICITY - A SUGGESTED ROLE FOR BETA-ADRENERGIC COMPOUNDS1981
- Invitro and invivo studies with adriamycin liposomesBiochemical and Biophysical Research Communications, 1979
- ADRIAMYCIN-INDUCED CARDIOTOXICITY (CARDIOMYOPATHY AND CONGESTIVE HEART-FAILURE) IN RATS1977
- AdriamycinAnnals of Internal Medicine, 1974